H.C. Wainwright has initiated coverage on MannKind (MNKD, Financial) with a Buy rating, setting a price target of $9. The firm believes that the current market valuation of MannKind does not fully account for both the challenges and opportunities associated with its Tyvaso royalty. According to the research notes, MannKind's pipeline is considered to be largely underappreciated by investors at its present share price.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for MannKind Corp (MNKD, Financial) is $9.43 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies an upside of 144.90% from the current price of $3.85. More detailed estimate data can be found on the MannKind Corp (MNKD) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, MannKind Corp's (MNKD, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for MannKind Corp (MNKD, Financial) in one year is $8.04, suggesting a upside of 108.83% from the current price of $3.85. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the MannKind Corp (MNKD) Summary page.
